BLAINJECTIONINJECTABLE
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
PLEGRIDY (peginterferon beta-1a) by Biogen is 12. First approved in 2014.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLEGRIDY is a pegylated interferon beta-1a indicated for relapsing forms of multiple sclerosis. Its precise mechanism of action in MS is unknown, though it is believed to modulate immune response through interferon signaling. It is administered subcutaneously every 14 days as a disease-modifying therapy.
Peak
Peak-stage biologic with established market presence; commercial teams are optimizing market access and defending share against emerging competitors.
Mechanism of Action
12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. 12.2 Pharmacodynamics There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. 12.3 Pharmacokinetics After single-dose or…
Worked on PLEGRIDY at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.